Modulation of gene expression in human osteoblasts by targeting a distal promoter region of human estrogen receptor-alpha gene.
Estrogen receptor (ER) alpha is expressed during osteoblast differentiation; however, both its functional role in bone metabolism and its involvement in osteoporotic pathogenesis caused by estrogen deficiency are not well understood. Loss of ER alpha gene expression could be one of the mechanisms leading to osteoporosis. Therefore, we investigated a possible modulation of ER alpha gene expression in a human osteoblastic cell line and in four primary osteoblast cultures by using a decoy strategy. Double stranded DNA molecules, mimicking a regulatory region of the ER alpha gene promoter (DNA-102) and acting as a 'silencer' in breast cancer cells, were introduced into osteoblasts as 'decoy' cis-elements to bind and functionally inactivate a putative negative transcription factor, and thus to induce ER alpha gene expression. We found that the DNA-102 molecule was able to specifically bind osteoblast nuclear proteins. Before decoy treatment, absence or variable low levels of ER alpha RNAs in the different cultures were detected. When the cells were transfected with the DNA-102 decoy, an increase in expression of ER alpha and osteoblastic markers, such as osteopontin, was observed, indicating a more differentiated osteoblastic phenotype both in the cell line and in primary cultures. These results showed that the DNA-102 sequence competes with endogenous specific negative transcription factors that may be critical for a decrease in or lack of ER alpha gene transcription. Therefore, osteoblastic transfection with the DNA-102 decoy molecule may be considered a tempting model in a putative therapeutic approach for those pathologies, such as osteoporosis, in which the decrease or loss of ER alpha expression plays a critical role in bone function.
Lambertini
E
E
Dipartimento di Biochimica e Biologia Molecolare, University of Ferrara, Via L. Borsari 46, 44100 Ferrara, Italy.
Penolazzi
L
L
Sollazzo
V
V
Pezzetti
F
F
de Mattei
M
M
del Senno
L
L
Traina
G C
GC
Piva
R
R
D015415:Biomarkers / Q000032:analysis; D015153:Blotting, Western; D002454:Cell Differentiation; D002478:Cells, Cultured; D024202:Electrophoretic Mobility Shift Assay; D047628:Estrogen Receptor alpha; D005786:Gene Expression Regulation; D006801:Humans; D008954:Models, Biological; D010010:Osteoclasts / Q000166:cytology / Q000378:metabolism*; D015676:Osteonectin / Q000032:analysis; D053495:Osteopontin; D010024:Osteoporosis / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D011401:Promoter Regions, Genetic; D011960:Receptors, Estrogen / Q000235:genetics* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012795:Sialoglycoproteins / Q000032:analysis
D015415:Biomarkers; D047628:Estrogen Receptor alpha; D015676:Osteonectin; D011960:Receptors, Estrogen; C506895:SPP1 protein, human; D012795:Sialoglycoproteins; D053495:Osteopontin